***PKTX...Protokinetix Investors..Some Interesting Facts about Macular Degeneration... :+)
***Macular degeneration, a leading cause of vision loss in Americans 60 years and older, affects as many as 11 million people in the United States – and experts predict the number will double to almost 22 million by 2050.
***Risk factors for macular degeneration include age, smoking, obesity and a poor diet.
...Age-related macular degeneration (AMD), which affects the retina at the back of the eyeball, impedes central vision. Symptoms include blurry vision, dark spots, distortions, wavy lines, and colors appearing “washed-out” or faded.
***Age-related macular degeneration currently affects 2.1 percent of Americans over 40, with the risk increasing to 30 percent for those over 75. Risk factors for age-related macular degeneration include being over 60, being overweight and smoking cigarettes (in fact, smokers have quadruple the risk of developing AMD compared to those who never smoked).
***Having high blood pressure, high cholesterol, being Caucasian and having a family history of the disease can also raise risk. Of course, diet plays an important role, with studies showing that consuming large amounts of (toxic) saturated fats raises risk.
***With No Known cure for Macular Degeneration..Dr. Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia..Along with Protokinetix is working on the cure..
PROTOKINETIX ENTERS INTO 3RD PHASE OF RETINAL CELL REPLACEMENT THERAPY TESTING AT UBC..
ProtoKinetix, Incorporated (www.protokinetix.com) (the "Company" or "ProtoKinetix") (OTCQB:PKTX) has entered into the 3rd phase of testing in retinal cell replacement therapy at the University of British Columbia. Due to the positive results from the first two phases of testing where the AAGP® treated cells showed a dramatic increase in survivability versus untreated cells over a four-week period, we are now expanding the study. The new study shall include two animal models over a longer period of time to test whether the AAGP® treated cells continue to develop into retinal cells to potentially restore vision in humans. The study conducted by the Gregory-Evans Retinal Therapeutic Lab at the University of British Columbia.
